Table 1 Summary of current FDA-approved CAR-T cell therapies
From: Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)-T cell therapies
Proper Name | Tradename | STN# | Target antigen | Manufacturer | Indications | Co-stimulatory domain |
|---|---|---|---|---|---|---|
idecabtagene vicleucel | ABECMA | 125736 | BCMA | Celgene Corporation, a Bristol-Myers Squibb Company | Relapsed or refractory multiple myeloma | 4-1BB |
lisocabtagene maraleucel | BREYANZI | 125714 | CD19 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B | 4-1BB |
ciltacabtagene autoleucel | CARVYKTI | 125746 | BCMA | Janssen Biotech, Inc | Relapsed or refractory multiple myeloma | 4-1BB |
tisagenlecleucel | KYMRIAH | 125646 | CD19 | Novartis Pharmaceuticals Corporation | Relapsed or refractory follicular lymphoma after two or more lines of therapy | 4‐1BB |
brexucabtagene autoleucel | TECARTUS | 125703 | CD19 | Kite Pharma, Inc | Relapsed or refractory mantle cell lymphoma (MCL), relapsed or refractory (r/r) B-cell precursor acute lymphoblastic leukemia (ALL) | 4-1BB |
axicabtagene ciloleucel | YESCARTA | 125643 | CD19 | Kite Pharma Inc | Refractory or relapsed large B-cell lymphoma | CD28 |